Petroleo Brasileiro SA, the Brazilian state-run oil producer, and drugmaker Merck & Co. led at least $54 billion of bond sales in the U.S. this week, the most in more than four months, as relative yields widened.
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, said price cuts will accelerate volume sales of its medicines in emerging markets led by China as the company extends its reach to less well-off patients.
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
Merck & Co., Bristol-Myers Squibb Co. and Roche Holding AG have opened a new front against cancer with the next generation of experimental drugs that use the human immune system to seek and destroy tumor cells.
Merck & Co. and GlaxoSmithKline Plc will cut the prices of their cervical cancer vaccines for some countries in the first large-scale effort to get the shots to millions of girls in the world’s poorest regions.
Merck & Co., facing generic competition to what was once its best-selling drug, cut its full-year guidance in anticipation of lower sales and said it would start buying back as much as $15 billion in shares.